Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker UPB
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Abigail P. Johnson | 3.79M | 6.9% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | FMR LLC | 3.79M | 6.9% | SCHEDULE 13G/A ↗ |
| Oct 29, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Xiangmin Cui | 2.72M | 4.9% | SCHEDULE 13G/A ↗ |
| Oct 29, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Decheng Capital Management IV (Cayman), LLC | 2.72M | 4.9% | SCHEDULE 13G/A ↗ |
| Oct 29, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Decheng Capital Global Life Sciences Fund IV, L.P. | 2.72M | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 12, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Norges Bank | 4.21M | 7.7% | SCHEDULE 13G/A ↗ |
| Jul 30, 2026 | SCHEDULE 13G | UPB Upstream Bio, Inc. | BlackRock, Inc. | 2.81M | 5.2% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Xiangmin Cui | 2.72M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Decheng Capital Global Healthcare GP, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Decheng Capital Global Healthcare Fund (Master), LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Decheng Capital Management IV (Cayman), LLC | 2.72M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Decheng Capital Global Life Sciences Fund IV, L.P. | 2.72M | 5.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Chen Yu | 2.12M | 3.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | TCG Crossover Fund I, L.P. | 2.12M | 3.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | TCG Crossover GP I, LLC | 2.12M | 3.9% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | HBM Healthcare Investments (Cayman) Ltd. | 2.20M | 4.1% | SCHEDULE 13G/A ↗ |
| Oct 24, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | Norges Bank | 2.88M | 5.3% | SCHEDULE 13G ↗ |
| Aug 6, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Abigail P. Johnson | 7.94M | 14.8% | SCHEDULE 13G/A ↗ |
| Aug 6, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | FMR LLC | 7.94M | 14.8% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | Xiangmin Cui | 3.29M | 6.1% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | Decheng Capital Global Healthcare GP, LLC | 200,000 | 0.4% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | Decheng Capital Global Healthcare Fund (Master), LP | 200,000 | 0.4% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | Decheng Capital Management IV (Cayman), LLC | 3.09M | 5.8% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | Decheng Capital Global Life Sciences Fund IV, L.P. | 3.09M | 5.8% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | Chen Yu | 2.80M | 5.2% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | TCG Crossover Fund I, L.P. | 2.80M | 5.2% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | TCG Crossover GP I, LLC | 2.80M | 5.2% | SCHEDULE 13G ↗ |
| Feb 13, 2025 | SCHEDULE 13G | UPB Upstream Bio, Inc. | HBM Healthcare Investments (Cayman) Ltd. | 2.72M | 5.1% | SCHEDULE 13G ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | Abigail P. Johnson | 7.18M | 13.4% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | UPB Upstream Bio, Inc. | FMR LLC | 7.18M | 13.4% | SCHEDULE 13G/A ↗ |
30 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances